This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Jiann-Kae Luo: Innovator in Protein Purity Determination
Introduction
Jiann-Kae Luo is a notable inventor based in White Plains, NY (US). He has made significant contributions to the field of biochemistry, particularly in the area of protein purity determination. His innovative work has implications for the manufacturing of bispecific antibodies, which are crucial in therapeutic applications.
Latest Patents
Jiann-Kae Luo holds a patent for a method titled "Multimeric protein purity determination." This patent focuses on improved capillary zone electrophoresis (CZE), affinity capillary electrophoresis (ACE), and partially filled-ACE (PF-ACE) systems. These systems are designed for the detection and quantification of specific molecular entities in a mixture. The patent addresses the challenge of quantifying heterodimeric bispecific antibodies, which are often produced alongside homodimer species. The disclosed methods enable the detection of specific homodimers in the mixture, enhancing the accuracy of quantification.
Career Highlights
Jiann-Kae Luo is currently employed at Regeneron Pharmaceuticals, Inc., where he continues to advance his research in biochemistry and protein analysis. His work at Regeneron has positioned him as a key player in the development of innovative solutions for complex biological challenges.
Collaborations
Jiann-Kae Luo collaborates with Kathir Muthusamy, who is also a valuable contributor to their projects. Their combined expertise fosters a productive environment for innovation and research.
Conclusion
Jiann-Kae Luo's contributions to the field of protein purity determination exemplify the importance of innovation in biochemistry. His patent and ongoing work at Regeneron Pharmaceuticals highlight his commitment to advancing scientific knowledge and improving therapeutic processes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
